Peer review is the system used to assess the quality of a manuscript before it is published. When a manuscript is first submitted to a journal, it is assessed to see if it meets the criteria for submission. If it does, the editorial team will then select potential independent reviewers within the field of research to peer-review the manuscript and make recommendations specific to originality, validity and significance. The major advantage of this process is that peer-reviewed articles provide a trusted form of scientific communication. Since scientific knowledge is cumulative and builds on itself, this trust is particularly important.
On September 12, 2024, a lawsuit was filed on behalf of a professor at UCLA. The case is pending in the United States District Court – Eastern District of New York.
The lawsuit alleges that six large for-profit publishers of peer-reviewed scholarly journals have colluded and conspired to “unlawfully appropriate billions of dollars that would have otherwise funded scientific research.”
Their alleged collusion consists of three parts.
First, scholars are not compensated for their work, namely the peer review services. Second, the publisher defendants agreed not to compete with each other for manuscripts by requiring scholars to submit their manuscripts to only one journal at a time. A single submission prevents competition among the defendant publishers to review manuscripts promptly and to publish those that demonstrate meritorious research. Third, the publishers agreed to prohibit scholars from freely sharing the scientific and medical advancements described in submitted manuscripts while those manuscripts are under peer review. Peer review may take over a year until full publication.
In addition, the scholars often sign away their intellectual property rights to their manuscripts and do not receive any compensation, monetary or otherwise. The defendant publishers then publish the scientific information in journals that often have hefty subscription costs for institutions and individuals alike. It is estimated one publisher generated $3.8 billion in revenue from its peer-reviewed journals with an operating profit margin of 38 percent.
The lawsuit seeks treble damages and injunctive and other relief, including an order to enjoin the defendants from continuing to violate the Sherman Act law by requiring them to dissolve the challenged unlawful agreements. As the case progresses, we will continue to provide relevant updates.
Academic Journal Publishers Antitrust Litigation (2024)
Academic Publications Draft Complaint (Final Version) (September 12, 2024)
6 major academic publishers face antitrust lawsuit
Peer review practices are “delaying science,” academic claims in lawsuit against six publishers.
Are you an
ObG Insider?
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site